...
gkos-img

Glaukos Corp, Common Stock

GKOS

NYQ

$150.564

-$2.11

(-1.38%)

1D
Industry: Health Care Equipment & Supplies Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.34B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
372.83K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.03
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$74.75 L
$153.5 H
$150.564

About Glaukos Corp, Common Stock

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. more

Industry: Health Care Equipment & SuppliesSector: Health Care

Returns

Time FrameGKOSSectorS&P500
1-Week Return6.21%2.44%2.57%
1-Month Return8.48%-4.49%0.09%
3-Month Return19.76%-8.82%4.76%
6-Month Return30.87%-4.46%9.89%
1-Year Return91.34%3.16%26.47%
3-Year Return229.67%-0.83%25.98%
5-Year Return175.58%35.65%86.34%
10-Year Return389.01%101.94%189.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue236.98M224.96M294.01M282.86M314.71M[{"date":"2019-12-31","value":75.3,"profit":true},{"date":"2020-12-31","value":71.48,"profit":true},{"date":"2021-12-31","value":93.42,"profit":true},{"date":"2022-12-31","value":89.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue38.59M91.72M66.63M68.98M75.58M[{"date":"2019-12-31","value":42.07,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.64,"profit":true},{"date":"2022-12-31","value":75.21,"profit":true},{"date":"2023-12-31","value":82.4,"profit":true}]
Gross Profit198.40M133.24M227.38M213.88M239.14M[{"date":"2019-12-31","value":82.96,"profit":true},{"date":"2020-12-31","value":55.72,"profit":true},{"date":"2021-12-31","value":95.09,"profit":true},{"date":"2022-12-31","value":89.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin83.72%59.23%77.34%75.61%75.99%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.75,"profit":true},{"date":"2021-12-31","value":92.38,"profit":true},{"date":"2022-12-31","value":90.32,"profit":true},{"date":"2023-12-31","value":90.77,"profit":true}]
Operating Expenses248.69M256.79M290.26M316.20M367.84M[{"date":"2019-12-31","value":67.61,"profit":true},{"date":"2020-12-31","value":69.81,"profit":true},{"date":"2021-12-31","value":78.91,"profit":true},{"date":"2022-12-31","value":85.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(50.29M)(123.55M)(62.87M)(102.31M)(128.70M)[{"date":"2019-12-31","value":-5029200000,"profit":false},{"date":"2020-12-31","value":-12355300000,"profit":false},{"date":"2021-12-31","value":-6287200000,"profit":false},{"date":"2022-12-31","value":-10231300000,"profit":false},{"date":"2023-12-31","value":-12870000000,"profit":false}]
Total Non-Operating Income/Expense860.00K(20.50M)(28.48M)(27.46M)(9.50M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2383.37,"profit":false},{"date":"2021-12-31","value":-3311.51,"profit":false},{"date":"2022-12-31","value":-3193.14,"profit":false},{"date":"2023-12-31","value":-1104.19,"profit":false}]
Pre-Tax Income(50.04M)(132.31M)(49.27M)(98.43M)(133.73M)[{"date":"2019-12-31","value":-5003600000,"profit":false},{"date":"2020-12-31","value":-13231400000,"profit":false},{"date":"2021-12-31","value":-4926700000,"profit":false},{"date":"2022-12-31","value":-9842900000,"profit":false},{"date":"2023-12-31","value":-13372700000,"profit":false}]
Income Taxes(65.46M)(11.97M)326.00K766.00K934.00K[{"date":"2019-12-31","value":-7008.57,"profit":false},{"date":"2020-12-31","value":-1281.16,"profit":false},{"date":"2021-12-31","value":34.9,"profit":true},{"date":"2022-12-31","value":82.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes15.42M(120.35M)(49.59M)(99.19M)(134.66M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}]
Income From Continuous Operations15.42M(120.35M)(49.59M)(99.19M)(134.66M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income15.42M(120.35M)(49.59M)(99.19M)(134.66M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}]
EPS (Diluted)(0.98)(1.96)(0.84)(2.19)(2.27)[{"date":"2019-12-31","value":-98,"profit":false},{"date":"2020-12-31","value":-196,"profit":false},{"date":"2021-12-31","value":-84,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-227,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GKOS
Cash Ratio 3.66
Current Ratio 5.54
Quick Ratio 4.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GKOS
ROA (LTM) -7.74%
ROE (LTM) -26.10%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GKOS
Debt Ratio Lower is generally better. Negative is bad. 0.28
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.72

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GKOS
Trailing PE NM
Forward PE NM
P/S (TTM) 23.14
P/B 12.47
Price/FCF NM
EV/R 22.85
EV/Ebitda NM
PEG 1.64

FAQs

What is Glaukos Corp share price today?

Glaukos Corp (GKOS) share price today is $150.564

Can Indians buy Glaukos Corp shares?

Yes, Indians can buy shares of Glaukos Corp (GKOS) on Vested. To buy Glaukos Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GKOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Glaukos Corp be purchased?

Yes, you can purchase fractional shares of Glaukos Corp (GKOS) via the Vested app. You can start investing in Glaukos Corp (GKOS) with a minimum investment of $1.

How to invest in Glaukos Corp shares from India?

You can invest in shares of Glaukos Corp (GKOS) via Vested in three simple steps:

  • Click on Sign Up or Invest in GKOS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Glaukos Corp shares
What is Glaukos Corp 52-week high and low stock price?

The 52-week high price of Glaukos Corp (GKOS) is $153.5. The 52-week low price of Glaukos Corp (GKOS) is $74.75.

What is Glaukos Corp price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Glaukos Corp (GKOS) is

What is Glaukos Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Glaukos Corp (GKOS) is 12.47

What is Glaukos Corp dividend yield?

The dividend yield of Glaukos Corp (GKOS) is 0.00%

What is the Market Cap of Glaukos Corp?

The market capitalization of Glaukos Corp (GKOS) is $8.34B

What is Glaukos Corp’s stock symbol?

The stock symbol (or ticker) of Glaukos Corp is GKOS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top